Physio-Control compliance status
This article was originally published in The Gray Sheet
Executive Summary
Redmond, Washington-based Lilly subsidiary found in compliance with good manufacturing practices and medical device reporting regulations following a recent FDA inspection. The firm still awaits FDA clearance of 510(k)s for changes made to its devices. The company has been barred from manufacturing or selling products in the U.S. since entering a consent decree with FDA in July 1992 ("The Gray Sheet" July 27, 1992, p. 1) and failed an initial reinspection in late 1992. Under the consent decree, the firm has to gain special FDA authorization to market its devices following the resolution of regulatory issues. Physio- Control says it will initially ask FDA to authorize sales of its Lifepak 10 external defibrillator and then will seek an okay for sales of the Lifepak 9 and Lifepak 300 products.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.